Several studies have found that the number of clinical depression cases has surged significantly to epidemic proportions in recent decades, from little-mentioned misery at the margins of the society in the early years to the current phenomenon that is rarely far from the news. The growth of north american antidepressants drugs, devices and therapies market at a CAGR of 1.27% during the forecasting years of 2019-2027.

NORTH AMERICA ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET FORECAST 2019-2027

North America Antidepressants Drugs, Devices and Therapies Market by Antidepressants Drugs (Serotonin and Norepinephrine Reuptake Inhibitors (Snris), Tricyclic Antidepressants (Tca), Monoamine Oxidase Inhibitors (Maois), Atypical Antidepressants, Selective Serotonin Reuptake Inhibitors, Benzodiazepines, Anticonvulsants, Beta-blockers, Other Antidepressants Drugs) by Devices (Deep Brain Stimulators, Fisher Wallace Stimulators, Transcranial Magnetic Stimulator, Other Devices) by Therapies (Cognitive Behavior Therapy (Cbt), Electroconvulsive Therapy (Ect), Rational Emotive Behavior Therapy (Rebt), Other Therapies) by Geography.

Request free sample

Report Summary

Several studies have found that the number of clinical depression cases has surged significantly to epidemic proportions in recent decades, from little-mentioned misery at the margins of the society in the early years to the current phenomenon that is rarely far from the news. It is possible that depression can be the combinatorial result of disturbing life events, certain medications, excessive use of a drug, etc. Certain predominant symptoms of depression include a general loss of interest, lack of energy, the inability to experience pleasure, and thinking of self-harm or harming others. It is a treatable mental illness, can be cured through support groups, psychotherapy, and antidepressant drug treatments. The North American region is found to be the largest in terms of diagnosed patients, devices manufacturers and many psychiatrists and psychologists that have contributed to the growth of the antidepressants drugs, devices and therapies market at a CAGR of 1.27% during the forecasting years of 2019-2027.

The regional market of North America is expected to procure $XX million in the year 2027, the highest among other regional markets for antidepressants drugs, devices and therapies, reasoned due to several factors such as the developed healthcare system and growing mental health treatment spending in the major regional countries of the United States and Canada. Although, the adoption of alternative treatments for depression, like meditation, yoga and VR technologies, can hinder the growth of the market in the said region. The expenditure for mental healthcare is the highest in the US as compared to other countries since in 2015, nearly 10.3 % US residential adults between 18 years to 25 years age group were diagnosed and treated for depression.

The branded drug manufacturers in North America have made billions of dollars by devising market exclusivity and multiple patents. Some of these market players are Boehringer Ingelheim GmbH, H. Lundbeck AS, Mayo Clinic, Eli Lilly and Company, Neuronetics, F. Hoffmann-La Roche Ltd., Brainsway, Abbot Laboratories, Pfizer, Allergan PLC, and GlaxoSmithKline.

To request a free sample copy of this report, please complete the form below:

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

    Table of Contents

    1. RESEARCH SCOPE
      • STUDY GOALS
      • SCOPE OF THE MARKET STUDY
      • WHO WILL FIND THIS REPORT USEFUL?
      • STUDY AND FORECASTING YEARS
    2. RESEARCH METHODOLOGY
      • SOURCES OF DATA
        • SECONDARY DATA
        • PRIMARY DATA
      • TOP-DOWN APPROACH
      • BOTTOM-UP APPROACH
      • DATA TRIANGULATION
    3. EXECUTIVE SUMMARY
      • MARKET SUMMARY
      • KEY FINDINGS
        • SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IS THE DOMINANT DRUG IN ANTIDEPRESSANTS MARKET
        • DEEP BRAIN STIMULATOR IS EXPECTED TO GROW FAST AMONG OTHER DEVICES OVER THE FORECAST PERIOD
        • COGNITIVE BEHAVIOR THERAPY (CBT) IS THE LARGEST CONTRIBUTOR TO ANTIDEPRESSANTS THERAPIES MARKET
    1. MARKET DYNAMICS
      • MARKET DEFINITION & SCOPE
      • MARKET DRIVERS
        • RISE IN THE NUMBER OF DEPRESSION PATIENTS
        • INCREASE IN AGING POPULATION
        • RISING CONSCIOUSNESS OF DEPRESSION AS A MEDICAL DISORDER
        • SURGE IN SALES OF ANTIDEPRESSANTS
      • MARKET RESTRAINTS
        • HIGH COST OF DEPRESSION THERAPY
        • PATENT EXPIRATION FACED BY THE COMPANIES
        • DELAY IN PRODUCT LAUNCHES
      • MARKET OPPORTUNITIES
        • HUGE MARKET POTENTIAL
        • MORE PREFERENCE FOR PERSONNEL THERAPY & DEVICE TREATMENT
      • MARKET CHALLENGES
        • STIFF COMPETITION FROM THE GENERIC DRUGMAKERS
    1. MARKET BY ANTIDEPRESSANTS DRUGS
      • SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIs)
      • TRICYCLIC ANTIDEPRESSANTS (TCA)
      • MONOAMINE OXIDASE INHIBITORS (MAOIs)
      • ATYPICAL ANTIDEPRESSANTS
      • SELECTIVE SEROTONIN REUPTAKE INHIBITORS
      • BENZODIAZEPINES
      • ANTICONVULSANTS
      • BETA-BLOCKERS
      • OTHER ANTIDEPRESSANTS DRUGS
    2. MARKET BY DEVICES
      • DEEP BRAIN STIMULATORS
      • FISHER WALLACE STIMULATORS
      • TRANSCRANIAL MAGNETIC STIMULATOR
      • OTHER DEVICES
    3. MARKET BY THERAPIES
      • COGNITIVE BEHAVIOR THERAPY (CBT)
      • ELECTROCONVULSIVE THERAPY (ECT)
      • RATIONAL EMOTIVE BEHAVIOR THERAPY (REBT)
      • OTHER THERAPIES
    4. KEY ANALYTICS
      • PORTER’S FIVE FORCE MODEL
        • THREAT OF NEW ENTRANTS
        • THREAT OF SUBSTITUTE
        • BARGAINING POWER OF SUPPLIERS
        • BARGAINING POWER OF BUYERS
        • THREAT OF COMPETITIVE RIVALRY
      • OPPORTUNITY MATRIX
      • VENDOR LANDSCAPE
      • VALUE CHAIN ANALYSIS
        • FOR DRUGS
        • FOR DEVICES
      • KEY BUYING CRITERIA
    5. GEOGRAPHICAL ANALYSIS
      • NORTH AMERICA
        • UNITED STATES
        • CANADA
    1. COMPETITIVE LANDSCAPE
      • MARKET SHARE ANALYSIS
      • COMPANY PROFILE
        • ABBOT LABORATORIES
        • ALLERGAN PLC
        • BOEHRINGER INGELHEIM GMBH
        • BRAINSWAY
        • ELI LILLY AND COMPANY
        • HOFFMANN-LA ROCHE LTD.
        • GLAXOSMITHKLINE
        • LUNDBECK AS
        • MAYO CLINIC
        • NEURONETICS
        • PFIZER

    TABLE LIST

     

    TABLE 1 NORTH AMERICA ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET, BY COUNTRY, 2019-2027, (IN $ MILLION)

    TABLE 2 LANDSCAPE OF DRUG EXPIRY AND LAUNCHES IN THE UNITED STATES

    TABLE 3 NORTH AMERICA ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET, BY ANTIDEPRESSANTS DRUGS, 2019-2027, (IN $ MILLION)

    TABLE 4 NORTH AMERICA ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET, BY DEVICES, 2019-2027, (IN $ MILLION)

    TABLE 5 NORTH AMERICA ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET, BY THERAPIES, 2019-2027, (IN $ MILLION)

    TABLE 6 OPPORTUNITY MATRIX

    TABLE 7 VENDOR LANDSCAPE

    TABLE 8 NORTH AMERICA ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET, BY COUNTRY, 2019-2027 (IN $ MILLION)

    FIGURE LIST

    FIGURE 1 NORTH AMERICA ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET SHARE, BY DRUGS, 2018 & 2027 (%)

    FIGURE 2 SNRIs MARKET, 2019 – 2027 (IN $ MILLION)

    FIGURE 3 DEEP BRAIN STIMULATORS MARKET, 2019-2027 (IN $ MILLION)

    FIGURE 4 COGNITIVE BEHAVIOR THERAPY (CBT) MARKET ($ MILLION)

    FIGURE 5 NORTH AMERICA ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET, BY COGNITIVE BEHAVIOR THERAPY (CBT), 2019-2027, (IN $ MILLION)

    FIGURE 6 NORTH AMERICA ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET, BY ELECTROCONVULSIVE THERAPY (ECT), 2019-2027, (IN $ MILLION)

    FIGURE 7 NORTH AMERICA ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET, BY RATIONAL EMOTIVE BEHAVIOR THERAPY (REBT), 2019-2027, (IN $ MILLION)

    FIGURE 8 NORTH AMERICA ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET, OTHER THERAPIES, 2019-2027, (IN $ MILLION)

    FIGURE 9 PORTER’S FIVE FORCE MODEL

    FIGURE 10 VALUE CHAIN OF ANTIDEPRESSANT DRUGS

    FIGURE 11 VALUE CHAIN ANALYSIS FOR DEVICE MARKET

    FIGURE 12 NORTH AMERICA ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET, REGIONAL OUTLOOK, 2018 & 2027, (%)

    FIGURE 13 UNITED STATES ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET, 2019-2027 (IN $ MILLION)

    FIGURE 14 CANADA ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET, 2019-2027 (IN $ MILLION

    FIGURE 15 MARKET SHARE OF ANTIDEPRESSANTS DRUG MANUFACTURERS (PERCENTAGE OF SALES), 2018

    Segmentation

    1. GEOGRAPHICAL ANALYSIS
      • NORTH AMERICA
        • UNITED STATES
        • CANADA
    1. MARKET BY ANTIDEPRESSANTS DRUGS
      • SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIs)
      • TRICYCLIC ANTIDEPRESSANTS (TCA)
      • MONOAMINE OXIDASE INHIBITORS (MAOIs)
      • ATYPICAL ANTIDEPRESSANTS
      • SELECTIVE SEROTONIN REUPTAKE INHIBITORS
      • BENZODIAZEPINES
      • ANTICONVULSANTS
      • BETA-BLOCKERS
      • OTHER ANTIDEPRESSANTS DRUGS
    2. MARKET BY DEVICES
      • DEEP BRAIN STIMULATORS
      • FISHER WALLACE STIMULATORS
      • TRANSCRANIAL MAGNETIC STIMULATOR
      • OTHER DEVICES
    3. MARKET BY THERAPIES
      • COGNITIVE BEHAVIOR THERAPY (CBT)
      • ELECTROCONVULSIVE THERAPY (ECT)
      • RATIONAL EMOTIVE BEHAVIOR THERAPY (REBT)
      • OTHER THERAPIES

    Request Free Sample

    To request a free sample copy of this report, please complete the form below :

    We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

      Choose License Type

      Get In Touch

      Inquire Before Buying

      Customization

      Inkwood Research delivers customized reports as per the client's requirement to provide them with an edge in the competitive market

      Request Customization

      RELATED REPORTS